- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
-
- Ellen van der Aar
- Galapagos NV Mechelen Belgium
-
- Julie Desrivot
- Galapagos SASU Romainville France
-
- Sonia Dupont
- Galapagos SASU Romainville France
-
- Bertrand Heckmann
- Galapagos SASU Romainville France
-
- Ann Fieuw
- Galapagos NV Mechelen Belgium
-
- Simone Stutvoet
- Galapagos NV Mechelen Belgium
-
- Liesbeth Fagard
- Galapagos NV Mechelen Belgium
-
- Karen Van de Wal
- Galapagos NV Mechelen Belgium
-
- Eric Helmer
- Galapagos Biotech Limited Cambridge United Kingdom
Search this article
Description
<jats:title>Abstract</jats:title><jats:p>GLPG1690 is a novel autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis (IPF). We report phase 1 studies investigating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG1690 in healthy subjects. We performed a first‐in‐human randomized, double‐blind, placebo‐controlled trial of single (20, 60, 150, 300, 600, 1000, 1500 mg) and multiple (14 days: 150 mg twice daily; 600 and 1000 mg once daily) ascending oral doses of GLPG1690 (NCT02179502), and a randomized, open‐label, crossover relative bioavailability study to compare the PK of tablet and capsule formulations of GLPG1690 600 mg and to assess the effect of food on PK of the tablet formulation (NCT03143712). Forty and 13 subjects were randomized in the first‐in‐human and relative bioavailability studies, respectively. GLPG1690 was well tolerated, with no dose‐limiting toxicity at all single and multiple doses. GLPG1690 was rapidly absorbed and eliminated, with a median t<jats:sub>max</jats:sub> and mean t<jats:sub>1/2</jats:sub> of approximately 2 and 5 hours, respectively. GLPG1690 exposure increased with increasing dose (mean C<jats:sub>max</jats:sub>, 0.09‐19.01 µg/mL; mean AUC<jats:sub>0‐inf</jats:sub>, 0.501‐168 µg·h/mL, following single doses of GLPG1690 20‐1500 mg). PD response, evidenced by rapid reduction in plasma lysophosphatidic acid (LPA) C18:2 levels, increased with increasing GLPG1690 plasma levels, plateauing at approximately 80% reduction in LPA C18:2 at around 0.6 µg/mL GLPG1690. Tablet and capsule formulations had similar PK profiles, and no clinically significant food effect was observed when comparing tablets taken in fed and fasted states. The safety, tolerability, and PK/PD profiles of GLPG1690 support continued clinical development for IPF.</jats:p>
Journal
-
- The Journal of Clinical Pharmacology
-
The Journal of Clinical Pharmacology 59 (10), 1366-1378, 2019-04-23
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360580237185048320
-
- ISSN
- 15524604
- 00912700
-
- Data Source
-
- Crossref